Sign up
Pharma Capital
Why invest in COS?

Collagen Solutions heading for pivotal year in 2018, says broker

A first partnership agreement was signed with a South Korean company towards the end of 2017
x-ray
BigPicture
The trial has been running for eight years

Regenerative med-tech Collagen Solutions PLC (LON:COS) is set for a significant year in 2018 as results of a long-running cartilage implant trial are published, says broker Cenkos.

ChondroMimetic, a collagen-based scaffold for the treatment of small defects in the articular surface of the knee joint, has been on trial with 15 patients since 2009/10.

READ: Collagen Solutions shares surge after it inks South Korea deal

The company expects to report key clinical data this quarter and assuming a positive outcome, will apply for a European regulatory CE mark and look for additional partners for the product later in the year, Cenkos said.

A first partnership agreement was signed with a South Korean company towards the end of 2017.

Third revenue arm

ChondroMimetic will be the start of a third leg to the business if approved.

Currently, Collagen derives its revenues from two sources: the supply of tissue and biomaterials to a medical use standard for implants and research; and development work on customer-specific products.

Margins have been falling lately, but Cenkos believes this reflects bespoke development work being undertaken ahead of future revenues.

“The development cycle from initial customer identification through to first market sales of the customer’s medical device can take up to four to five years, during which Collagen will move through periods when revenues are received and periods with no income.” 

With a developing customer pipeline, Cenkos, the house broker, also forecasts growth in the biomaterials business going forward.

Sales rising

Sales this year (March 2018) are forecast at £4.3mln, rising to £5.7mln in 2019 and £10.2mln in 2020 when Cenkos forecasts a first profit.

“We believe the company is also strengthening its existing business stating its sales pipeline is ‘the strongest it has been’. We maintain our Buy recommendation.”

Shares are 2.5p.

PhilW.jpg


Register here to be notified of future COS Company articles
View full COS profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.